Elaine McWhirter

1.6k total citations
39 papers, 486 citations indexed

About

Elaine McWhirter is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elaine McWhirter has authored 39 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 14 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elaine McWhirter's work include Cancer Immunotherapy and Biomarkers (14 papers), CAR-T cell therapy research (11 papers) and Melanoma and MAPK Pathways (11 papers). Elaine McWhirter is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), CAR-T cell therapy research (11 papers) and Melanoma and MAPK Pathways (11 papers). Elaine McWhirter collaborates with scholars based in Canada, United States and South Korea. Elaine McWhirter's co-authors include Lisa Wang, Sébastien J. Hotte, Amit M. Oza, James R. Wright, Malcolm J. Moore, Ian F. Tannock, Eric Winquist, Lillian L. Siu, Som D. Mukherjee and Andrea Eisen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Elaine McWhirter

35 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elaine McWhirter Canada 13 300 204 83 81 80 39 486
Gretchen Taylor United States 8 322 1.1× 145 0.7× 118 1.4× 75 0.9× 54 0.7× 11 503
Dan He China 9 178 0.6× 226 1.1× 62 0.7× 62 0.8× 66 0.8× 21 404
Su Mei Cao China 6 281 0.9× 173 0.8× 137 1.7× 86 1.1× 140 1.8× 19 586
Yaewon Yang South Korea 13 380 1.3× 258 1.3× 125 1.5× 141 1.7× 115 1.4× 54 688
Konrad Klinghammer Germany 14 310 1.0× 235 1.2× 125 1.5× 181 2.2× 74 0.9× 53 580
Deanna Teoh United States 12 173 0.6× 253 1.2× 87 1.0× 74 0.9× 120 1.5× 20 708
Daniel Brungs Australia 14 322 1.1× 180 0.9× 175 2.1× 151 1.9× 77 1.0× 47 565
Emma Kipps United Kingdom 8 292 1.0× 268 1.3× 157 1.9× 94 1.2× 70 0.9× 26 693
Miso Kim South Korea 12 245 0.8× 181 0.9× 91 1.1× 156 1.9× 38 0.5× 30 463

Countries citing papers authored by Elaine McWhirter

Since Specialization
Citations

This map shows the geographic impact of Elaine McWhirter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elaine McWhirter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elaine McWhirter more than expected).

Fields of papers citing papers by Elaine McWhirter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elaine McWhirter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elaine McWhirter. The network helps show where Elaine McWhirter may publish in the future.

Co-authorship network of co-authors of Elaine McWhirter

This figure shows the co-authorship network connecting the top 25 collaborators of Elaine McWhirter. A scholar is included among the top collaborators of Elaine McWhirter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elaine McWhirter. Elaine McWhirter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yao, Xiaomei, Tara Baetz, Alexandra Easson, et al.. (2024). Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review. Surgical Oncology. 54. 102077–102077. 3 indexed citations
2.
Pond, Gregory R., et al.. (2024). Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use. Current Oncology. 31(1). 425–435. 3 indexed citations
3.
O’Kane, Grainne M., Jennifer L. Spratlin, D-Y. Oh, et al.. (2024). 44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy. Annals of Oncology. 35. S22–S22. 1 indexed citations
4.
Li, Yuchen, Gregory R. Pond, & Elaine McWhirter. (2023). Multisystem immune-related adverse events from dual agent immunotherapy use.. Journal of Clinical Oncology. 41(16_suppl). 2635–2635. 1 indexed citations
5.
Chan, Sze Wah Samuel, et al.. (2023). Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition. Current Oncology. 30(5). 4527–4537. 2 indexed citations
6.
Barron, Carly C., et al.. (2023). Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. Journal for ImmunoTherapy of Cancer. 11(8). e006500–e006500. 37 indexed citations
7.
8.
Baetz, Tara, et al.. (2020). Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. Cancer Treatment Reviews. 87. 102032–102032. 12 indexed citations
9.
10.
Hogg, David, Jose Gerard Monzon, Scott Ernst, et al.. (2020). Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. Current Oncology. 27(4). 204–214. 6 indexed citations
11.
Pond, Gregory R., et al.. (2019). Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients?. Journal of Cutaneous Medicine and Surgery. 23(6). 586–594. 9 indexed citations
12.
13.
McWhirter, Elaine, Ian Quirt, Thomas F. Gajewski, et al.. (2016). A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Investigational New Drugs. 34(2). 231–235. 7 indexed citations
14.
Chiu, Joanne, Sébastien J. Hotte, Christian Kollmannsberger, et al.. (2015). A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Investigational New Drugs. 34(1). 104–111. 15 indexed citations
15.
Haas, Naomi B., Ian Quirt, Sébastien J. Hotte, et al.. (2014). Phase II trial of vorinostat in advanced melanoma. Investigational New Drugs. 32(3). 526–534. 47 indexed citations
16.
Wolpin, Brian M., Eileen M. O’Reilly, Yoo-Joung Ko, et al.. (2013). Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of Oncology. 24(7). 1792–1801. 29 indexed citations
17.
Richter, Suzanne, Philippe L. Bédard, Eric Xueyu Chen, et al.. (2013). A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational New Drugs. 32(2). 243–249. 68 indexed citations
18.
19.
Sridhar, Srikala S., Eric Winquist, Andrea Eisen, et al.. (2010). A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational New Drugs. 29(5). 1045–1049. 65 indexed citations
20.
McWhirter, Elaine, et al.. (2007). Baseline radiological staging in primary breast cancer: impact of educational interventions on adherence to published guidelines. Journal of Evaluation in Clinical Practice. 13(4). 647–650. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gretchen Taylor Breakdown of academic impact, for papers by Dan He Breakdown of academic impact, for papers by Su Mei Cao Breakdown of academic impact, for papers by Yaewon Yang Breakdown of academic impact, for papers by Konrad Klinghammer Breakdown of academic impact, for papers by Deanna Teoh Breakdown of academic impact, for papers by Daniel Brungs Breakdown of academic impact, for papers by Emma Kipps Breakdown of academic impact, for papers by Miso Kim
Rankless by CCL
2026